LSD-induced hallucinogen persisting perception disorder with depressive features treated with reboxetine: Case report

We would like to present the case of a patient who had a prior history of cannabis, ecstasy (MDM A) and LSD abuse and who developed both Hallucinogen Persisting Perception Disorder (HPPD) and a major depressive episode. Following two unsuccessful SSRIs trials, reboxetine was prescribed. During a six-month follow-up period on reboxetine 6 mg./day, no exacerbation of the visual disturbance or recurrence of the depressive features were reported. Reboxetine may have an α₂ adrenoreceptor modulating effect on both noradrenaline and serotonin release, thus reboxetine's α₂ adrenoreceptor modulating effect on noradrenaline release may affect sympathetic activity and be involved in the recovery process.